Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia
Author(s)
Type
Journal Article
Abstract
Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has advanced to a stage where many patients achieve very low or undetectable levels of disease. Remarkably, some of these patients remain in sustained remission when treatment is withdrawn, suggesting that they may be at least operationally cured of their disease. Accurate definition of deep molecular responses (MRs) is therefore increasingly important for optimal patient management and comparison of independent data sets. We previously published proposals for broad standardized definitions of MR at different levels of sensitivity. Here we present detailed laboratory recommendations, developed as part of the European Treatment and Outcome Study for CML (EUTOS), to enable testing laboratories to score MR in a reproducible manner for CML patients expressing the most common BCR-ABL1 variants.
Date Issued
2015-02-27
Date Acceptance
2015-01-21
Citation
Leukemia, 2015, 29 (5), pp.999-1003
ISSN
1476-5551
Publisher
Nature Publishing Group
Start Page
999
End Page
1003
Journal / Book Title
Leukemia
Volume
29
Issue
5
Copyright Statement
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
License URL
Sponsor
Bristol Myers Squibb
Grant Number
n/a
Subjects
Science & Technology
Life Sciences & Biomedicine
Oncology
Hematology
MINIMAL RESIDUAL DISEASE
POLYMERASE-CHAIN-REACTION
HARMONIZING CURRENT METHODOLOGY
CHRONIC MYELOGENOUS LEUKEMIA
BCR-ABL TRANSCRIPTS
INTERNATIONAL SCALE
CANCER PROGRAM
PCR
IMATINIB
STANDARDIZATION
Calibration
Europe
Fusion Proteins, bcr-abl
Gene Expression Profiling
Gene Expression Regulation, Leukemic
Genetic Variation
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Limit of Detection
Polymerase Chain Reaction
Protein-Tyrosine Kinases
Reproducibility of Results
Treatment Outcome
Immunology
1103 Clinical Sciences
1112 Oncology And Carcinogenesis
Publication Status
Published